NCT00943124View on ClinicalTrials.gov

MK0524B Bioequivalence Study (0524B-070)

PHASE1CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Dyslipidemia
Interventions
DRUG

MK0524B (ER niacin (+) laropiprant (+) simvastatin)

Single dose of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg) in one of two treatment periods.

DRUG

MK0524A (ER niacin + laropiprant)

Single dose of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) in one of two treatment periods.

DRUG

Simvastatin

Single dose simvastatin (Zocor™) 20 mg in one of two treatment periods.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00943124 - MK0524B Bioequivalence Study (0524B-070) | Biotech Hunter | Biotech Hunter